In the future, new biomarkers should appear with the use of certain polymorphic variations of the germinative line, such as EGF+61 A/G,VEGF – 460 C/T, and CLPTM1L C/T, as biomarkers of risk and prognosis of non-small cell lung cancer, and may be an additional help to clinical oncologists during treatment of these patients. This evidence concerns the gene EGF and non-small cell lung carcinoma.